Pfizer: Myelodysplastic Syndromes trials
The registry lists 13 Myelodysplastic Syndromes studies with Pfizer as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 9Phase 2 4Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMMLCompletedNCT04842604Phase 3Results posted
- Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDSTerminatedNCT02706899Phase 1/2Results posted
- A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsTerminatedNCT02663518Phase 1Results posted
- A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML PatientsCompletedNCT02367456Phase 1Results posted
- A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01546038Phase 2Results posted
- Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous MalignanciesCompletedNCT01461538Phase 2Results posted
- AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)CompletedNCT00071006Phase 2Results posted
- A Safety Study of SEA-CD70 in Patients With Myeloid MalignanciesActive, not recruitingNCT04227847Phase 1
- A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic SyndromesCompletedNCT01496495Phase 1
- Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological MalignanciesCompletedNCT01399840Phase 1
- A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic SyndromeCompletedNCT00916227Phase 1
- A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT00502112Phase 1
- A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT00283114Phase 1